NRIX
Nurix Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$26.14
+3.24%Aug 20, 2026, 11:00 UTC
Nurix Therapeutics appointed Wes Burwell as its Chief Human Resources Officer on August 20, 2026.
Source:Aug 11, 2026, 05:21 UTC
Nurix Therapeutics' stock reached a new 52-week high of $26.04 on Tuesday after Royal Bank of Canada raised its price target.
Source:Aug 4, 2026, 11:00 UTC
Nurix Therapeutics earned a $10 million milestone payment after collaborator Sanofi initiated a Phase 1 clinical trial of the oral STAT6 degrader SAR448272/NX-3911 for type 2 inflammatory diseases.
Source:Jul 21, 2026, 20:01 UTC
Nurix Therapeutics announced HSR clearance for its global collaboration with Roche to co-develop and co-commercialize bexobrutideg.
Source:Jul 9, 2026, 22:26 UTC
Nurix Therapeutics, Inc. reported its quarterly financial results for Q2 2026, with a loss of $0.81 per share.
Source:Jun 26, 2026, 16:05 UTC
Nurix Therapeutics entered a collaboration with Roche for bexobrutideg, including a $700 million upfront payment and potential milestone payouts of up to $2.3 billion.